Emerging drugs for the treatment of anxiety

Aripiprazole as Augmentation Treatment of Refractory Generalized Anxiety Disorder and Panic Disorder

(2016) Elizabeth A. Hoge et al.   CNS SPECTRUMS

Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders

(2015) N. Singewald et al.   PHARMACOLOGY & THERAPEUTICS

FAAH genetic variation enhances fronto-amygdala function in mouse and human

(2015) Iva Dincheva et al.   Nature Communications

Amygdala-Hippocampal Volume and the Phenotypic Heterogeneity of Posttraumatic Stress Disorder

(2015) Robert H. Pietrzak et al.   JAMA Psychiatry

The Dopamineβ-Hydroxylase Inhibitor, Nepicastat, Reduces Different Alcohol-Related Behaviors in Rats

(2014) Giancarlo Colombo et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Conditional Inactivation of Neuropeptide Y Y1 Receptors Unravels the Role of Y1 and Y5 Receptors Coexpressing Neurons in Anxiety

(2014) Angela Longo et al.   BIOLOGICAL PSYCHIATRY

The endocannabinoid system modulates stress, emotionality, and inflammation

(2014) Molly S. Crowe et al.   BRAIN BEHAVIOR AND IMMUNITY

Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders

(2014) Olena Bukalo et al.   BRITISH JOURNAL OF PHARMACOLOGY

Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder

(2014) Pablo Roitman et al.   CLINICAL DRUG INVESTIGATION

Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents

(2014) Daniel F Connor et al.   EXPERT OPINION ON PHARMACOTHERAPY

A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder

(2014) Atul R. Mahableshwarkar et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder

(2014) Michael E. Thase et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Agomelatine in Generalized Anxiety Disorder

(2014) Dan J. Stein et al.   JOURNAL OF CLINICAL PSYCHIATRY

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

(2014) Le-Ben Wan et al.   JOURNAL OF CLINICAL PSYCHIATRY

Effect of Pregabalin Augmentation in Treatment of Patients with Combat-Related Chronic Posttraumatic Stress Disorder

(2014) MEHDI BANIASADI et al.   Journal of Psychiatric Practice

A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes

(2014) A. McGirr et al.   PSYCHOLOGICAL MEDICINE

Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial

(2014) Boadie W Dunlop et al.   Trials

The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology

(2014) Bruce N. Cuthbert   World Psychiatry

Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder

(2014) Adriana Feder et al.   JAMA Psychiatry

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

(2013) James W. Murrough et al.   AMERICAN JOURNAL OF PSYCHIATRY

Neuropeptide Y Receptor Gene Expression in the Primate Amygdala Predicts Anxious Temperament and Brain Metabolism

(2013) Patrick H. Roseboom et al.   BIOLOGICAL PSYCHIATRY

FROM THE NEUROBIOLOGY OF EXTINCTION TO IMPROVED CLINICAL TREATMENTS

(2013) Filomene G. Morrison et al.   DEPRESSION AND ANXIETY

Vortioxetine: First Global Approval

(2013) Andrew Gibb et al.   DRUGS

Treatment of anxiety disorders in epilepsy: An evidence-based approach

(2013) Marco Mula   EPILEPSIA

The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?

(2013) Lee A Dawson   Expert Opinion on Drug Discovery

Glutamate-based anxiolytic ligands in clinical trials

(2013) Joanna M Wierońska et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression

(2013) Dan J Stein et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

An Open-Label Study of Guanfacine Extended Release for Traumatic Stress Related Symptoms in Children and Adolescents

(2013) Daniel F. Connor et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study

(2013) A Neumeister et al.   MOLECULAR PSYCHIATRY

50 years of hurdles and hope in anxiolytic drug discovery

(2013) Guy Griebel et al.   NATURE REVIEWS DRUG DISCOVERY

D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial

(2013) JoAnn Difede et al.   NEUROPSYCHOPHARMACOLOGY

Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept

(2013) Carolyn I Rodriguez et al.   NEUROPSYCHOPHARMACOLOGY

Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats

(2013) L.I. Serova et al.   NEUROSCIENCE

Cerebrospinal fluid neuropeptide Y in combat veterans with and without posttraumatic stress disorder

(2013) Renu Sah et al.   PSYCHONEUROENDOCRINOLOGY

The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons

(2013) Pim Cuijpers et al.   World Psychiatry

Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder

(2012) Michael H. Bloch et al.   BIOLOGICAL PSYCHIATRY

EFFECTS OF ARIPIPRAZOLE AUGMENTATION IN TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER (A DOUBLE BLIND CLINICAL TRIAL)

(2012) Mehdi Sayyah et al.   DEPRESSION AND ANXIETY

Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States

(2012) Anthony J. Rothschild et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial

(2012) Leszek Bidzan et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Synergistic mechanisms involved in the antidepressant effects of agomelatine

(2012) Daniela Tardito et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder

(2012) David S. Baldwin et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Agomelatine Prevents Relapse in Generalized Anxiety Disorder

(2012) Dan J. Stein et al.   JOURNAL OF CLINICAL PSYCHIATRY

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

(2012) Guy Griebel et al.   NATURE REVIEWS DRUG DISCOVERY

Biological studies of post-traumatic stress disorder

(2012) Roger K. Pitman et al.   NATURE REVIEWS NEUROSCIENCE

Endocannabinoid system and mood disorders: Priming a target for new therapies

(2012) Vincenzo Micale et al.   PHARMACOLOGY & THERAPEUTICS

Central functions of neuropeptide Y in mood and anxiety disorders

(2011) Gang Wu et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Pregabalin augmentation in treatment-resistant obsessive–compulsive disorder

(2011) Panagiotis Oulis et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder

(2011) Charles Merideth et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Evidence-based pharmacological treatment of generalized anxiety disorder

(2011) David S. Baldwin et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD

(2011) John H. Krystal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder

(2011) Arifulla Khan et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Effect of Aripiprazole Augmentation of Serotonin Reuptake Inhibitors or Clomipramine in Treatment-Resistant Obsessive-Compulsive Disorder

(2011) Maria Rosaria A. Muscatello et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

(2011) Benny Bang-Andersen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

(2011) Mateus M Bergamaschi et al.   NEUROPSYCHOPHARMACOLOGY

Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder

(2011) Amy L. Mahan et al.   TRENDS IN NEUROSCIENCES

Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects

(2011) Eva Marco   Frontiers in Behavioral Neuroscience

Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties

(2010) John E. Tellew et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists

(2010) John H. Krystal et al.   CNS DRUGS

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

(2010) Vladimir Coric et al.   DEPRESSION AND ANXIETY

The relationship between anxiety disorders and suicide attempts: findings from the National Epidemiologic Survey on Alcohol and Related Conditions

(2010) Josh Nepon et al.   DEPRESSION AND ANXIETY

Therapeutic potential of neuropeptide Y (NPY) receptor ligands

(2010) Shaun P. Brothers et al.   EMBO Molecular Medicine

A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial

(2010) Sanjay J. Mathew et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The Burden of Anxiety Disorders on the Family

(2010) Rhandi Senaratne et al.   JOURNAL OF NERVOUS AND MENTAL DISEASE

Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial

(2010) Marcelo Feijo Mello et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

Low Cerebrospinal Fluid Neuropeptide Y Concentrations in Posttraumatic Stress Disorder

(2009) Renu Sah et al.   BIOLOGICAL PSYCHIATRY

Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder

(2009) Michael W. Otto et al.   BIOLOGICAL PSYCHIATRY

Severity of anxiety and work-related outcomes of patients with anxiety disorders

(2009) Steven R. Erickson et al.   DEPRESSION AND ANXIETY

Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder

(2009) Johannes Tauscher et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care

(2009) E. Martin-Merino et al.   FAMILY PRACTICE

Cannabis and anxiety: a critical review of the evidence

(2009) José Alexandre Crippa et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial

(2009) Siegfried Kasper et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus

(2009) Amélie Soumier et al.   NEUROPSYCHOPHARMACOLOGY

The psychiatric side-effects of rimonabant

(2009) Fabrício A. Moreira et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

Central CRH system in depression and anxiety — Evidence from clinical studies with CRH1 receptor antagonists

(2008) Florian Holsboer et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Efficacy of Agomelatine in Generalized Anxiety Disorder

(2008) Dan J. Stein et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Social anxiety disorder

(2008) Murray B Stein et al.   LANCET

Functional Interactions between Endocannabinoid and CCK Neurotransmitter Systems May Be Critical for Extinction Learning

(2008) Jasmeer P Chhatwal et al.   NEUROPSYCHOPHARMACOLOGY

Neurokinin1 Antagonists Potentiate Antidepressant Properties of Serotonin Reuptake Inhibitors, Yet Blunt Their Anxiogenic Actions: A Neurochemical, Electrophysiological and Behavioral Characterization

(2008) Alain Gobert et al.   NEUROPSYCHOPHARMACOLOGY

Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder

(2007) J. R. Strawn et al.   DEPRESSION AND ANXIETY